A1M Pharma AB has changed its name to Guard Therapeutics International AB
Our vision is to save lives. That is why we are dedicated to developing tomorrow’s drugs against oxidative stress, something that will make a substantial contribution towards saving lives but also has the potential to prevent and treat serious kidney diseases.
A1M Pharma is dedicated to developing a drug that can prevent oxidative stress, which could provide a better life for millions of people with acute kidney damage. ROSgard, our biological drug candidate, mimics one of the body’s most powerful and universal defense systems against oxidative stress. Designed with a natural “homing” to the kidneys, ROSgard prevents kidney damage by protecting, cleaning and repairing the exposed cells and tissues.
The objective is to develop ROSgard with an initial focus on acute kidney damage associated with heart surgery. Our strategy is to demonstrate treatment efficacy in the relevant patient group in a time- and cost-efficient manner. Partnerships and licensing agreements with strategically chosen partners are constantly evaluated in order to maximize ROSgard's endogenous potential and generate value for patients and owners. There are grounds for expanding the clinical programme in the future, both in acute kidney injury and in other indications. There are also possibilities to widen the company's pipeline.
Equipped for the future
We are well equipped to face the challenges ahead. A first and very attractive area of indication has been identified, and we have strenghened and established a leading competence within the field of acute kidney damage. Today, we have a well-defined clinical development plan, and financing has been secured for our ongoing phase I study.
About us and our operating activitiesRead more